Cambridge Trust Co. Grows Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Cambridge Trust Co. grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,857 shares of the company’s stock after purchasing an additional 525 shares during the quarter. Cambridge Trust Co.’s holdings in Novo Nordisk A/S were worth $10,434,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Cornerstone Planning Group LLC purchased a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $29,000. Tower Research Capital LLC TRC lifted its stake in Novo Nordisk A/S by 165.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock worth $32,000 after purchasing an additional 124 shares in the last quarter. Pacific Center for Financial Services lifted its stake in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Valued Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $28,000. Finally, Copeland Capital Management LLC raised its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 141 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 1.5 %

NVO stock traded down $1.92 during mid-day trading on Thursday, hitting $122.61. 2,080,701 shares of the company were exchanged, compared to its average volume of 4,870,547. The company has a market capitalization of $550.22 billion, a PE ratio of 45.51, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The firm has a fifty day simple moving average of $126.28 and a 200 day simple moving average of $110.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. On average, research analysts forecast that Novo Nordisk A/S will post 3.33 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a $0.664 dividend. The ex-dividend date was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s payout ratio is 49.17%.

Analysts Set New Price Targets

NVO has been the subject of several research reports. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.